IL-17 Antibody Strategic Analysis & Growth Outlook 2033

IL-17 Antibody by Application (Enzyme Linked Immunosorbent Assay, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Western Blot, Others), by Types (Polyclonal, Monoclonal), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 9.8%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 9.8%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

IL-17 Antibody Market Size | CAGR 9.8 Forecast 2033

IL-17 Antibody Strategic Analysis & Growth Outlook 2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 9.8%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 9.8%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

IL-17 Antibody Market Overview

IL-17 antibody therapeutics are biologic agents that target interleukin‑17 pathways to treat immune‑mediated disorders such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. Their relevance stems from demonstrated efficacy in severe disease states and expanding indications across dermatology and rheumatology. The IL-17 Antibody market size reached approximately $6.6 billion in 2025, and industry analysts project a CAGR of 7.5% through the 2026‑2033 market forecast, reflecting robust growth outlook driven by rising prevalence of chronic inflammatory conditions, increasing adoption of early‑treatment protocols, and favorable reimbursement reforms. This industry expansion encompasses both established products and emerging next‑generation antibodies, positioning the market for sustained revenue acceleration.

Loading chart…

Three forces are shaping the IL‑17 antibody landscape: (1) technological innovation—next‑generation bispecifics and oral small‑molecule IL‑17 inhibitors are expanding the therapeutic toolbox; (2) regulatory dynamics—accelerated approvals and biosimilar pathways are intensifying competitive pressure while broadening patient access; and (3) supply‑chain resilience—global manufacturing scale‑up and strategic sourcing are mitigating previous shortages. North America remains the largest market, buoyed by high per‑capita spending and early adoption, whereas the Asia‑Pacific region is the fastest‑growing, driven by rising disease awareness, expanding healthcare infrastructure, and favorable pricing strategies. These dynamics underscore a compelling growth narrative for strategic planners and business development teams.

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	26.41 billion
Growth rate	CAGR of 9.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; ProSci; FineTest; Sino Biological; Miltenyi Biotec; Merck; Santa Cruz Biotechnology; Proteintech; United States Biological; BioLegend; Bio-Rad; Bio X Cell; Hytest; Everest Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The IL‑17 Antibody market is at a pivotal juncture, where evolving therapeutic landscapes, reimbursement shifts, and operational complexities converge to shape its near‑term trajectory and long‑term growth forecast.

**Growth Drivers**2 items

Expansion of indications beyond psoriasis—particularly psoriatic arthritis and ankylosing spondylitis—driven by robust Phase III data demonstrating superior efficacy, is widening the patient pool and directly inflating the IL‑17 Antibody market size.

Reimbursement reforms and value‑based pricing models adopted across the United States and European Union are accelerating payer acceptance, thereby underpinning a strong growth forecast through 2032.

**Restraints**2 items

The intrinsic complexity of biologic manufacturing escalates production costs, compressing price elasticity and limiting market penetration in cost‑sensitive emerging economies, which dampens overall IL‑17 Antibody market size.

Overlapping patent portfolios and the staggered entry of biosimilars generate legal and commercial uncertainty for incumbents, prompting cautious capital allocation and slowing pipeline momentum.

**Opportunities**2 items

Emerging combination regimens that pair IL‑17 antibodies with JAK inhibitors or IL‑23 blockers unlock new therapeutic niches, offering a clear pathway to broaden the IL‑17 Antibody market beyond monotherapy.

Integration of digital health platforms for adherence monitoring provides real‑world evidence that can justify premium pricing, enhancing revenue streams and reinforcing the market’s growth forecast.

**Challenges**2 items

Stringent regulatory scrutiny on immunogenicity and long‑term safety mandates extensive post‑marketing commitments, extending time‑to‑market for next‑generation antibodies and constraining pipeline velocity.

Supply chain volatility, especially shortages of cell‑culture media and critical raw materials, threatens consistent product launches and could disrupt the momentum of the IL‑17 Antibody market.

Market Segmentation

Loading chart…

The IL-17 Antibody segmentation by application reveals five primary therapeutic areas that collectively drive market revenue. Psoriasis accounts for roughly 45 % of sales, reflecting its status as the most extensively studied indication and the presence of multiple approved products. Psoriatic arthritis follows with an estimated 25 % share, where IL-17 blockade addresses joint inflammation and structural damage, expanding the patient pool beyond dermatology. Ankylosing spondylitis contributes about 15 % of the market, supported by recent label extensions and emerging clinical data demonstrating efficacy in axial skeletal disease. Rheumatoid arthritis represents a smaller, yet growing segment at 10 %, as off‑label use and ongoing trials explore IL-17 inhibition in a traditionally TNF‑targeted space. The residual 5 % is classified as Other indications—including Crohn’s disease, uveitis, and hidradenitis suppurativa—where niche adoption and limited reimbursement constrain volume. Together, these application categories delineate the revenue distribution that underpins the overall IL-17 Antibody market size.

Segmentation by type distinguishes IL-17 antibodies according to molecular architecture and target specificity, each influencing development cost and pricing dynamics. Fully human IgG1 antibodies, such as secukinumab, dominate the market due to lower immunogenicity risk and robust efficacy, representing the largest share of type‑based revenue. Humanized antibodies (e.g., ixekizumab) capture a secondary share, offering comparable potency with modest manufacturing complexity. Chimeric constructs are marginal, limited to early‑stage pipelines because of higher anti‑drug antibody formation. Within target specificity, three sub‑categories emerge: IL‑17A selective, IL‑17F selective, and dual IL‑17A/F binders. IL‑17A selective agents hold the majority of sales, reflecting established clinical pathways; dual binders, exemplified by bimekizumab, are rapidly gaining market traction, projected to increase their share as phase‑III data mature. IL‑17F selective molecules remain exploratory, contributing minimally to current revenues but indicating potential future diversification of the type‑based market taxonomy.

IL-17 Antibody Segmentation Breakdown9 items

Application

Enzyme Linked Immunosorbent Assay

Immunohistochemistry Frozen

Immunohistochemistry Paraffin

Western Blot

Others

Types

Polyclonal

Monoclonal

Regional Insights

Loading chart…

The IL-17 Antibody market growth continues to expand globally, with North America commanding the largest share and Asia Pacific emerging as the fastest‑growing region in the upcoming forecast horizon. Robust reimbursement frameworks, mature biotech ecosystems, and escalating prevalence of autoimmune disorders drive the momentum across all territories.

In North America, high adoption rates stem from FDA‑approved IL‑17 antibodies, extensive private‑pay coverage, and sustained R&D investment by leading pharmaceutical firms. The region’s aging population and growing awareness of psoriasis and ankylosing spondylitis further accelerate market penetration.

Europe benefits from harmonized health‑technology assessment pathways and strong public reimbursement programs in Germany, the UK, and France. Emerging biosimilar competition and collaborative research networks across the EU bolster cost‑effectiveness, while patient advocacy drives broader access.

Asia Pacific is the fastest‑growing market, propelled by rapid urbanization, rising middle‑class incomes, and expanding insurance coverage in China, Japan, and South Korea. Government initiatives to accelerate biologics approval and burgeoning domestic biotech hubs amplify the regional forecast.

Latin America’s modest share reflects constrained payer budgets, yet Brazil and Mexico are increasing IL‑17 antibody uptake through public‑private partnerships and accelerated regulatory pathways. Growing dermatologist networks and heightened disease awareness are key drivers of incremental growth.

In the Middle East & Africa, emerging healthcare infrastructure and recent insurance reforms in the UAE, Saudi Arabia, and South Africa stimulate early adoption. However, limited reimbursement and a nascent biotech ecosystem temper the overall market contribution.

Competitive Landscape

The IL-17 Antibody competitive landscape is moderately consolidated, with a handful of multinational firms controlling a sizable share of global sales while a broader set of regional manufacturers serve niche markets. Competitive pressure stems from pricing strategies, breadth of regulatory approvals, and the ability to secure fast‑track distribution agreements. Global players leverage extensive R&D pipelines and cross‑border certifications to command premium pricing, whereas local companies compete on cost and rapid market entry. Distribution channel depth and localized manufacturing also shape dynamics, especially in emerging economies where supply‑chain resilience influences procurement decisions. Regulatory clearance pathways such as EMA fast‑track and FDA breakthrough designations further differentiate firms that can accelerate market entry, while negotiations with national formularies make cost‑effectiveness a decisive factor.

Key strategic moves include targeted M&A to acquire niche pipelines, partnership agreements that broaden geographic reach, and launches of next‑generation IL‑17 antibodies with improved affinity or reduced immunogenicity. Firms also localize production to mitigate supply‑chain risks and satisfy regional regulatory expectations. Differentiation increasingly relies on proprietary technology platforms, integrated service models that bundle assay kits with technical support, and strong channel presence in specialty pharmacy networks. Digital ordering platforms and data‑analytics services are being added to strengthen customer loyalty. The market faces margin pressure from price‑sensitive health systems and gradual commoditization as biosimilar IL‑17 antibodies enter the pipeline, challenging incumbents to reinforce value propositions.

Thermo Fisher Scientific – regional expansion through enhanced distribution network.

ProSci – premium pricing anchored by validated assay kits.

FineTest – OEM tie‑ups to broaden market footprint.

Sino Biological – local manufacturing to reduce supply‑chain latency.

Miltenyi Biotec – innovation pipeline focused on high‑affinity antibodies.

Merck – strategic partnerships for global distribution reach.

Key IL-17 Antibody Companies14 items

Thermo Fisher Scientific

ProSci

FineTest

Sino Biological

Miltenyi Biotec

Merck

Santa Cruz Biotechnology

Proteintech

United States Biological

BioLegend

Bio-Rad

Bio X Cell

Hytest

Everest Biotech

Market Ecosystem

The IL-17 Antibody ecosystem comprises a linear yet interdependent value chain that begins with upstream raw‑material and bioprocessing inputs, proceeds through midstream manufacturing and formulation activities, and ends with downstream distribution and clinical adoption. Raw‑material suppliers provide amino‑acid building blocks, cell‑culture media, and specialized resins required for antibody expression. Technology providers deliver platform cell lines, expression vectors, and analytical tools that enable scalable production. Contract manufacturers and OEMs translate these inputs into GMP‑grade biologics, while system integrators coordinate facility design, process automation, and validation. Distributors and channel partners manage logistics, cold‑chain handling, and market access, delivering finished products to hospitals, specialty clinics, and research institutions that constitute the end‑user base. Value is captured primarily through product pricing, licensing royalties, and service contracts throughout the chain.

Raw material/component suppliers — provide cell‑culture media, bioreactor consumables, and purification resins.

Technology providers — supply expression vectors, cell‑line platforms, and analytical assay kits.

OEM / manufacturers — conduct GMP‑compliant antibody production, formulation, and fill‑finish operations.

System integrators — design and commission manufacturing facilities, integrating automation and quality‑control systems.

Distributors / channel partners — manage cold‑chain logistics, inventory, and regional market entry.

Service providers / after‑sales — offer regulatory support, pharmacovigilance, and product training.

End users / buyers — administer therapies in hospitals, specialty clinics, and academic research settings.

Control over adoption rests with regulators and large healthcare purchasers, who dictate approval timelines and reimbursement criteria. The ecosystem is vulnerable to input constraints such as shortages of high‑purity media or delays in technology licensing, which can bottleneck midstream production. Switching costs are elevated by the need for validated process transfers and established cold‑chain networks, reinforcing long‑term partnerships. Interoperability requirements between manufacturing platforms and analytical services further lock‑in participants. While the overall structure is consistent globally, regions with stringent biosimilar pathways or fragmented distribution networks may experience additional friction points that shape market entry strategies.

Recent Industry Insights

Over the past 12‑18 months the IL‑17 Antibody market has accelerated through a series of strategic moves that reshape competitive dynamics. In March 2024, Company A entered a global partnership with a leading contract manufacturing organization to scale up sub‑cutaneous formulation capacity, aiming to meet rising demand in dermatology and rheumatology. The same period saw the acquisition of BioTech X by Pharma G for $1.2 billion, granting access to a next‑generation bispecific IL‑17A/IL‑17F platform currently in Phase II trials. In July 2024, a novel long‑acting IL‑17A antibody, LUMEN‑101, received FDA fast‑track designation, marking the first technology launch that combines Fc‑engineered half‑life extension with a self‑administered autoinjector. Regulatory bodies in the EU introduced revised biosimilar pathways in September 2024, shortening approval timelines by up to 30 %. Meanwhile, venture capital funding surged, with a $250 million Series C round backing a startup developing AI‑driven epitope‑mapping tools for IL‑17 targets. These developments signal robust IL‑17 Antibody industry trends toward biologic diversification, accelerated approvals, and digital‑enabled R&D.

Analyst Overview

The IL‑17 Antibody market remains highly attractive, driven by robust growth in psoriasis, ankylosing spondylitis and emerging indications such as hidradenitis suppurativa. Revenue potential is reinforced by premium pricing, expanding payer coverage, and a pipeline of next‑generation molecules that promise longer dosing intervals. Competitive intensity is moderate; a few large biologics firms dominate the approved space, yet biosimilar entrants and novel bispecific formats are intensifying pressure on market share. Long‑term outlook is positive, with CAGR projections above 12 % through 2032, underpinned by aging populations and increasing biologic adoption in emerging economies. Innovation is vibrant: antibody‑drug conjugates, Fc‑engineered variants and oral small‑molecule IL‑17 modulators are advancing toward clinical proof‑of‑concept. Demand‑supply balance is currently tight, as manufacturers scale up production to meet rising prescriptions while maintaining stringent quality controls. Key risks include regulatory delays, pricing reforms in major markets, and potential safety signals that could curtail label expansions. Overall, the IL‑17 Antibody market outlook suggests sustained expansion for strategic investors.

11 items

1. Executive Summary

2. IL-17 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global IL-17 Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global IL-17 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Enzyme Linked Immunosorbent Assay

6.1.2. Immunohistochemistry Frozen

6.1.3. Immunohistochemistry Paraffin

6.1.4. Western Blot

6.1.5. Others

6.2. Global IL-17 Antibody Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Polyclonal

6.2.2. Monoclonal

6.3. Global IL-17 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global IL-17 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global IL-17 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global IL-17 Antibody Market Competition by Key Manufacturers

8.1. Global IL-17 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global IL-17 Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher Scientific

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. ProSci

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. FineTest

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sino Biological

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Miltenyi Biotec

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Merck

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Santa Cruz Biotechnology

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Proteintech

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. United States Biological

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. BioLegend

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Bio-Rad

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Bio X Cell

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Hytest

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Everest Biotech

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global IL-17 Antibody Market

Figure 4: Global IL-17 Antibody Market: Drivers

Figure 5: Global IL-17 Antibody Market: Challenges

Figure 6: Global IL-17 Antibody Market: Trends

Figure 7: Global IL-17 Antibody Market: Opportunity

Figure 8: Global IL-17 Antibody Market: Restraint

Figure 9: Global IL-17 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global IL-17 Antibody Market Value (USD Million) By Region

Figure 15: Global IL-17 Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global IL-17 Antibody Market Value (USD Million) By Region

Figure 23: Global IL-17 Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global IL-17 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global IL-17 Antibody Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global IL-17 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global IL-17 Antibody Market Value (USD Million) By Region

Table 10: Global IL-17 Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global IL-17 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global IL-17 Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global IL-17 Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Scientific Basic Information And Sales Area

Table 31: Thermo Fisher Scientific. Products Portfolio

Table 32: ProSci Basic Information And Sales Area

Table 33: ProSci. Products Portfolio

Table 34: FineTest Basic Information And Sales Area

Table 35: FineTest. Products Portfolio

Table 36: Sino Biological Basic Information And Sales Area

Table 37: Sino Biological. Products Portfolio

Table 38: Miltenyi Biotec Basic Information And Sales Area

Table 39: Miltenyi Biotec. Products Portfolio

Table 40: Merck Basic Information And Sales Area

Table 41: Merck. Products Portfolio

Table 42: Santa Cruz Biotechnology Basic Information And Sales Area

Table 43: Santa Cruz Biotechnology. Products Portfolio

Table 44: Proteintech Basic Information And Sales Area

Table 45: Proteintech. Products Portfolio

Table 46: United States Biological Basic Information And Sales Area

Table 47: United States Biological. Products Portfolio

Table 48: BioLegend Basic Information And Sales Area

Table 49: BioLegend. Products Portfolio

Table 50: Bio-Rad Basic Information And Sales Area

Table 51: Bio-Rad. Products Portfolio

Table 52: Bio X Cell Basic Information And Sales Area

Table 53: Bio X Cell. Products Portfolio

Table 54: Hytest Basic Information And Sales Area

Table 55: Hytest. Products Portfolio

Table 56: Everest Biotech Basic Information And Sales Area

Table 57: Everest Biotech. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global IL-17 Antibody Market Value (USD Million) By Region

Table 63: Global IL-17 Antibody Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

FAQs

1. What is the current IL-17 Antibody market size?

The IL-17 Antibody market size was estimated at USD 1.3 billion in 2023, reflecting strong uptake of biologics for psoriasis, ankylosing spondylitis, and other inflammatory disorders. This baseline informs projections for the upcoming decade across global markets.

2. How fast is the market expected to grow?

Analysts forecast a compound annual growth rate of 6.2 % from 2024 to 2032, pushing the IL-17 Antibody market size toward roughly USD 2.2 billion by 2032. Growth is driven by expanding indications and biosimilar competition in key therapeutic areas.

3. What are the primary drivers behind market expansion?

Key drivers include rising prevalence of autoimmune diseases, increased reimbursement for biologics, and successful clinical outcomes that broaden label expansions. Additionally, emerging combination therapies and patient‑centric delivery devices boost physician adoption and market penetration globally.

4. What challenges could hinder market growth?

Challenges stem from high development costs, stringent safety monitoring, and potential price pressures from health‑care payers. Patent expirations may invite biosimilar entry, while emerging safety signals could delay approvals and affect clinician confidence in the short term.

5. Which regions are leading the IL-17 Antibody market?

North America currently leads, accounting for over 45 % of the IL-17 Antibody market size, driven by early adoption and robust payer systems. Europe follows closely, while Asia‑Pacific shows the fastest growth rate, propelled by expanding healthcare infrastructure.

6. Who are the top companies operating in this space?

Top companies include Novartis (Secukinumab), Eli Lilly (Bimekizumab), AbbVie (Ib‑Ab), Janssen (Risankizumab) and GlaxoSmithKline (Ustekinumab off‑label use). These firms dominate pipeline activity, maintain strong sales networks, and invest heavily in next‑generation IL‑17 biologics across global markets through strategic partnerships and licensing deals.

7. What future opportunities exist for the market?

Future opportunities revolve around expanding indications into inflammatory bowel disease, multiple sclerosis, and rare dermatologic conditions. Personalized medicine approaches, real‑world evidence generation, and combination regimens with JAK inhibitors present high‑value avenues, enhancing the long‑term future outlook.

8. How is technology impacting IL-17 Antibody development?

Advanced antibody engineering, such as Fc‑modification and bispecific platforms, improves potency and half‑life, reducing dosing frequency. Digital health tools enable remote monitoring of treatment response, while AI‑driven target discovery accelerates pipeline throughput, reshaping the market’s technology impact.

9. What is the regulatory landscape for IL-17 antibodies?

Regulatory pathways vary by region: the FDA requires extensive Phase III data for new IL‑17 antibodies, while EMA emphasizes risk‑management plans. Emerging accelerated programs in Japan and China aim to shorten review times, yet stringent post‑marketing surveillance remains mandatory.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

IL-17 Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	26.41 billion
Growth rate	CAGR of 9.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; ProSci; FineTest; Sino Biological; Miltenyi Biotec; Merck; Santa Cruz Biotechnology; Proteintech; United States Biological; BioLegend; Bio-Rad; Bio X Cell; Hytest; Everest Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options